Business Context and Reporting Period
This Form 8-K is a current report filed by Harvard Bioscience, Inc. on February 28, 2006, regarding corporate governance changes. The report details the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The material change reported is the appointment of George Uveges as a new member of the Board of Directors. Key details include:
- Effective Date: The day after the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2005.
- Role: Class III Director with a term expiring in 2006.
- Committee Assignment: Appointed to the Audit Committee effective on the same day as his Board appointment.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, or contingencies. It references a press release issued on March 6, 2006, which is attached as Exhibit 99.1, but the text of that release is not included in this summary.
Investor Verification Checklist
- Verify the filing date of the Form 10-K for the fiscal year ended December 31, 2005, to determine the exact effective date of Mr. Uveges' appointment.
- Review the attached press release (Exhibit 99.1) for additional biographical details on Mr. Uveges.
- Confirm the composition of the Audit Committee following this appointment.